HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.
Margalida Calafat,Carles Suria,Francisco Mesonero,Ruth de Francisco,Carmen Yagüe Caballero,Luisa de la Peña,Alejandro Hernández-Camba,Ainhoa Marcé,Beatriz Gallego,Noelia Martín-Vicente,Montserrat Rivero,Marisa Iborra,Iván Guerra,Marta Carrillo-Palau,Lucía Madero,Beatriz Burgueño,David Monfort,Gisela Torres,Marta Teller,Juan Ángel Ferrer Rosique,Pablo Vega Villaamil,Cristina Roig,Angel Ponferrada-Diaz,Elena Betoré Glaría,Yamile Zabana,Javier P Gisbert,David Busquets,Noelia Alcaide,Blau Camps,Jesús Legido,Maria González-Vivo,Marta Maia Bosca-Watts,Isabel Pérez-Martínez,Diego Casas Deza,Jordi Guardiola,Laura Arranz Hernández,Mercè Navarro,Carla J Gargallo-Puyuelo,Fiorella Cañete,Míriam Mañosa,Eugeni Domènech,Javier P. Gisbert,Carla J. Gargallo-Puyuelo,the ENEIDA registry of GETECCU
DOI: https://doi.org/10.14309/ajg.0000000000002965
2024-07-17
The American Journal of Gastroenterology
Abstract:Background: The coexistence of human immunodeficiency virus (HIV) infection and inflammatory bowel disease (IBD) is uncommon. Data on the impact of HIV on IBD course and its management is scarce. Aim: To describe the IBD phenotype, therapeutic requirements and prevalence of opportunistic infections (OI) in IBD patients with a coexistent HIV infection. Methods: Case-control, retrospective study including all HIV positive patients diagnosed with IBD in the ENEIDA registry. Patients with positive HIV serology (HIV-IBD) were compared to controls (HIV seronegative), matched 1:3 by year of IBD diagnosis, age, gender and type of IBD. Results: A total of 364 patients (91 HIV-IBD and 273 IBD controls) were included. In the whole cohort, 58% had ulcerative colitis (UC), 35% had Crohn's disease (CD) and 7% were IBD unclassified. The HIV-IBD group presented a significantly higher proportion of proctitis in UC and colonic location in CD but fewer extraintestinal manifestations than controls. Regarding treatments, non-biological therapies (37.4% vs. 57.9%; P=0.001) and biologicals (26.4% vs. 42.1%; P=0.007), were used less frequently among patients in the HIV-IBD group. Conversely, HIV-IBD patients developed more OI than controls regardless of non-biological therapies use. In the multivariate analysis, HIV infection (OR 4.765, 95%CI 2.48-9.14; P<0.001) and having ≥1 comorbidity (OR 2.445, 95%CI 1.23-4.85; P=0.010) were risk factors for developing OI, while CD was protective (OR 0.372, 95%CI 0.18-0.78;P=0.009). Conclusions: HIV infection appears to be associated with a less aggressive phenotype of IBD and a lesser use of non-biological therapies and biologicals but entails a greater risk of developing OI.
gastroenterology & hepatology